发明名称 |
Methods and compositions for reducing amyloid beta levels |
摘要 |
The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity. |
申请公布号 |
US9347085(B2) |
申请公布日期 |
2016.05.24 |
申请号 |
US201414219556 |
申请日期 |
2014.03.19 |
申请人 |
The J. David Gladstone Institutes |
发明人 |
Gan Li;Mucke Lennart |
分类号 |
G01N33/53;A61K39/00;A61K39/395;C12Q1/37;A61K38/55;C07K16/38;C12N15/113;G01N33/68;A61K31/7052;C12Q1/68;A61K38/00 |
主分类号 |
G01N33/53 |
代理机构 |
Bozicevic, Field & Francis LLP |
代理人 |
Rubin Michael B.;Bozicevic, Field & Francis LLP |
主权项 |
1. A method of reducing the level of human amyloid beta protein in a cell or a tissue, the method comprising contacting the cell or tissue with an antibody that selectively reduces cystatin C levels and/or activity in the cell or tissue, wherein reduction of cystatin C levels and/or activity results in a reduced level of human amyloid beta protein in the cell or tissue. |
地址 |
San Francisco CA US |